Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Daniel J. Lovell, MD, MPH
Daniel J. Lovell, MD, MPH, is the Joseph E. Levinson Professor of Pediatrics at the University of Cincinnati Medical Center, and Immediate Past Chairman, Pediatric Rheumatology Collaborative Study Group (PRCSG). Dr Lovell’s clinical interests include the diagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases while his research interests focus on clinical trials in children with rheumatic diseases, the methodology of clinical trials, and the mentoring of junior faculty. He has authored more than 150 peer-reviewed publications and numerous meeting abstracts on these topics. He has had NIH funding for over 24 continuous years.
His entire research career has been focused on identifying and evaluating more effective treatments for children with rheumatic diseases. For 30 years he chaired an international network of pediatric rheumatology centers called the Pediatric Rheumatology Collaborative Study Group (PRCSG). Almost all the new therapies approved by the Food and Drug Administration for use in the treatment of children with rheumatic diseases in the last 30 years were approved based on studies performed by the PRCSG. He loves being a grandfather and finds it to be a wonderful, never-ending source of joy.
Monday, November 13, 2023
12:00 PM – 1:00 PM PT
Disclosure(s): Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Canadian Arthritis Society: Advisor or Review Panel Member (Ongoing); Celgene: Consultant (Ongoing); Forest Research: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Hoffmann-La Roche: Consultant (Ongoing); Janssen: Consultant (Ongoing); NIH-NIAMS: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); United Bioscience Corporation: Consultant (Ongoing); Wyeth: Consultant (Ongoing)
Pediatric Great Debate Introduction
Monday, November 13, 2023
12:00 PM – 12:05 PM PT
Disclosure(s): Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Canadian Arthritis Society: Advisor or Review Panel Member (Ongoing); Celgene: Consultant (Ongoing); Forest Research: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Hoffmann-La Roche: Consultant (Ongoing); Janssen: Consultant (Ongoing); NIH-NIAMS: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); United Bioscience Corporation: Consultant (Ongoing); Wyeth: Consultant (Ongoing)
14T142: Clinical Trials for Pediatric Disease: The Current Landscape
Tuesday, November 14, 2023
2:00 PM – 3:00 PM PT
Disclosure(s): Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Canadian Arthritis Society: Advisor or Review Panel Member (Ongoing); Celgene: Consultant (Ongoing); Forest Research: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Hoffmann-La Roche: Consultant (Ongoing); Janssen: Consultant (Ongoing); NIH-NIAMS: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); United Bioscience Corporation: Consultant (Ongoing); Wyeth: Consultant (Ongoing)
